No correlation was observed between creatinine levels and MMP-9 levels (= 00138) and APLA (= 0041)

No correlation was observed between creatinine levels and MMP-9 levels (= 00138) and APLA (= 0041). of SLE patients compared with sera samples of healthy controls. High activity levels of MMP-9 were determined in sera of 68% of the SLE patients. Elevated levels of MMP-9 were correlated with the presence of discoid rash, Raynaud phenomenon, pneumonitis, mucosal ulcers and anti-phospholipid antibodies. Changes in activity levels of MMP-9, but not of MMP-2, were observed in sera of the same patient at different periods of the disease course. High levels of MMP-9 did not correlate with disease activity index (SLEDAI, BILAG) in female patients, but correlated with SLE activity in the group of male patients. The results of the present study suggest that MMP-9 plays a role in the pathogenesis of SLE. suppresses oedema, pathologic tissue proliferation, and damage to specialized tissue structures in several inflammatory and autoimmune diseases [14,22,23]. In the present study, we determined the levels of MMP-9 and MMP-2 in sera of 40 patients with SLE, and we demonstrate that MMP-9, but not MMP-2, activity is significantly elevated in sera of SLE patients compared with healthy controls. High MMP-9 activity correlated with the presence of discoid rash, Raynaud phenomenon, pneumonitis, mucosal ulcers and the presence of anti-phospholipid antibodies (APLA). In addition, elevated levels of MMP-9 correlated with SLE activity in the group of male patients. MATERIALS AND METHODS Patients Forty patients, 32 females and eight males with SLE participated in this study. All patients revealed at least four of the revised diagnostic criteria of the American College of Rheumatism (ACR) for the diagnosis of SLE [2]. Twenty-five sex-and age-matched healthy volunteers served as a control group in our studies. The mean age of patients at diagnosis was 29 97 (range 15C48) years and the mean follow-up period was 11 10 (range 1C32) years. Disease activity was determined according to the SLEDAI lupus activity index [24] and by the BILAG index [25]. The study was approved by the ethic committee of the Kaplan Medical Center. Measurement of MMP-2 and MMP-9 by activity assay kits Activities of MMP-2 and MMP-9 were measured by specific Biotrak MMP-2 or MMP-9 activity assay kits (Amersham Pharmacia Biotech UK Limited, Little Chalfont, UK) according to the manufacturers instructions. Sera were diluted 1:100 and 1:32 for the determination of MMP-2 and MMP-9 activities, respectively. The appropriate standards were added in each assay. In order to measure the total content of the MMPs, activation of the pro form of the MMPs was performed using unpublished results). Thus, we were interested in studying whether MMP-9 is also elevated in sera of SLE patients. For this purpose, we examined sera of 40 SLE patients and 25 healthy controls by gel zymography, in which both MMP-9 and MMP-2 activities can be visualized. A representative gel is shown in Fig. 1. As can BAPTA be seen in BAPTA this figure, levels of MMP-9 Cryab are elevated in the sera of SLE patients compared with healthy controls. Densitometric analysis of the zymograms of sera of 40 SLE patients and 25 healthy controls indicated that the mean MMP-9 activity for SLE patients was 109 56 densitometry units and for BAPTA the healthy controls, 765 42 densitometry units (= 00001). Activity values of above 85 densitometry units (mean of healthy controls + 2 s.e.) were considered high. The results demonstrated high activity levels BAPTA of MMP-9 in 68% of the SLE patients. Only 3% of healthy controls exhibited high MMP-9 activity (= 0001). Densitometric analysis of MMP-2 levels in the same serum samples revealed that the differences in MMP-2 activity between sera of SLE patients and of healthy controls were not significant. Thus, values of 109 7 and 123 5.